Akero Therapeutics, an early stage biotech developing therapies for NASH and other metabolic diseases, raised $92 million by offering 5.75 million shares at $16, the high end of the $14 to $16 range. The company originally filed to offer 5.0 million shares. Insiders had indicated an interest in purchasing up to $30 million of the IPO (33% of the deal).
Akero Therapeutics plans to list on the Nasdaq under the symbol AKRO. J.P. Morgan, Jefferies and Evercore ISI acted as joint book-running managers on the deal.
